Cloverleaf Bio
Cloverleaf Bio Raises $33M Seed Round for RNA Cancer Therapeutics
Cloverleaf Bio announced $33M in Seed financing on September 8, 2026. Cloverleaf Bio closed an oversubscribed $33 million seed round to advance engineered tRNA therapeutics for liver and colorectal cancers.
Round details
The financing includes backing from 4BIO Capital, AbbVie Ventures, Eli Lilly and Company, Boehringer Ingelheim Venture Fund. The company did not publish a valuation with the announcement.
- Round: Seed
- Capital announced: $33M
- Headquarters: New Haven, CT
How the company plans to use the capital
Cloverleaf Bio will advance an inhibitory tRNA program for hepatocellular carcinoma into early clinical testing and move an antibody-tRNA conjugate program for colorectal cancer through preclinical development.
Why this matters for GTM teams
The participation of three pharmaceutical investors at the preclinical stage indicates industry interest in engineered tRNA as a programmable therapeutic payload rather than only a research tool.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Cloverleaf Bio seed announcement.
Company Info
Investors (4)
Share
Related Reports
Basecamp Research Raises $140M Series C for AI-Designed Medicines
Basecamp Research raised a $140 million Series C led by S32 to train new EDEN models and advance AI-designed therapeutics toward clinical development.
Ema Raises $77M Series B to Expand Its Enterprise AI Employee Platform
Ema raised a $77 million Series B led by Creaegis, bringing total funding to $140 million as it scales AI agents across enterprise workflows.
Chamelio Raises $26M Series A for AI-Native Legal Operations
Chamelio raised a $26 million Series A led by Entrée Capital to replace legacy contract-management systems with agentic legal operations.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free